BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30514195)

  • 1. Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549).
    Coyne CP; Narayanan L
    Anticancer Agents Med Chem; 2019; 19(6):802-819. PubMed ID: 30514195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen.
    Coyne CP; Narayanan L
    Curr Pharm Des; 2018; 24(11):1224-1240. PubMed ID: 29141539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).
    Coyne CP; Narayanan L
    Drug Des Devel Ther; 2016; 10():2575-97. PubMed ID: 27574398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mebendazole in simultaneous combination with dexamethasone-(C
    Coyne CP; Narayanan L
    J Exp Ther Oncol; 2019 Dec; 13(2):81-118. PubMed ID: 31881126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549).
    Coyne CP; Narayanan L
    Chem Biol Drug Des; 2017 Mar; 89(3):379-399. PubMed ID: 27561602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine- (C
    Coyne CP; Narayanan L
    J Pharm Drug Deliv Res; 2015; 4(1):. PubMed ID: 26613088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.
    Coyne CP; Jones T; Bear R
    J Cancer Ther; 2015 Jan; 6(1):62-89. PubMed ID: 25821636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Neoplastic Cytotoxicity of Gemcitabine-(C
    Coyne CP; Jones T; Bear R
    J Cancer Res Ther Oncol; 2014 Apr; 2(1):. PubMed ID: 25844392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine-(C
    Coyne CP; Jones T; Bear R
    J Clin Exp Oncol; 2013; 2(2):. PubMed ID: 26251840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
    Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X
    Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.
    Xie Z; Wu K; Wang Y; Pan Y; Chen B; Cheng D; Pan S; Guo T; Du X; Fang L; Wang X; Ye F
    Eur J Med Chem; 2020 Feb; 187():111943. PubMed ID: 31846829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a prominent dual-target DDR1/EGFR inhibitor aimed DDR1/EGFR-positive NSCLC.
    Wang X; Lu Y; Chen S; Zhu Z; Fu Y; Zhang J; He J; Huang L; Luo L; Guo W; Xu Z; Xie Z; Xu X; Zhang Y; Ye F; Ma S
    Bioorg Chem; 2024 Aug; 149():107500. PubMed ID: 38823310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
    Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
    Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity.
    Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA
    Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Neoplastic Cytotoxicity of Gemcitabine-(C
    Coyne CP; Jones T; Bear R
    Med Chem (Los Angeles); 2013 May; 3(2):210-223. PubMed ID: 26225219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
    Aziz MW; Kamal AM; Mohamed KO; Elgendy AA
    Bioorg Med Chem Lett; 2021 Jun; 41():127987. PubMed ID: 33771586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties.
    Fang JK; Xu Z; Zhang Y; Zhang W; Liu B; Fang Y; Sun T
    Anticancer Agents Med Chem; 2016; 16(12):1665-1672. PubMed ID: 27349449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.